Biogen Sustainability Profile
Biogen Inc., a leading biotechnology company headquartered in the United States, has been at the forefront of neurological disease research since its founding in 1978. With a strong presence in North America, Europe, and Asia, Biogen focuses on developing innovative therapies for conditions such as multiple sclerosis, spinal muscular atrophy, and Alzheimer’s disease. Renowned for its pioneering work in monoclonal antibodies, Biogen's core products include the multiple sclerosis treatments Tecfidera and Ocrevus, which are distinguished by their efficacy and safety profiles. The company has achieved significant milestones, including the first FDA approval of a treatment for spinal muscular atrophy in 2016. As a key player in the biotechnology industry, Biogen continues to push the boundaries of science, solidifying its market position through a commitment to research and development, and a robust pipeline of potential therapies.
DitchCarbon Score
How does Biogen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biogen's score of 97 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Biogen's reported carbon emissions
In 2024, Biogen reported total carbon emissions of approximately 324,178,000 kg CO2e, with significant contributions from Scope 1, 2, and 3 emissions. Specifically, Scope 1 emissions accounted for about 56,611,000 kg CO2e, while Scope 2 emissions were approximately 507,000 kg CO2e (market-based) and 32,858,000 kg CO2e (location-based). The majority of emissions stemmed from Scope 3, totalling around 267,059,000 kg CO2e, which includes categories such as purchased goods and services (approximately 184,441,000 kg CO2e) and business travel (about 18,067,000 kg CO2e). Biogen has set ambitious climate commitments, aiming for a 55% reduction in absolute Scope 1 and 2 emissions by 2032 from a 2019 baseline. Furthermore, the company is working towards achieving net-zero emissions across its entire value chain by 2045. This includes a long-term goal of eliminating Scope 1 and 2 emissions entirely by 2040 and reducing Scope 3 emissions by 90% by 2045. These targets align with the Science Based Targets initiative (SBTi) and reflect Biogen's commitment to sustainable practices within the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 55,965,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 390,000 | 000,000 | 000,000 | 00,000 | 00,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | 235,589,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Biogen's Industry?
How Carbon Intensive is Biogen's Location?
Biogen's Scope 3 Categories Breakdown
Biogen's Scope 3 emissions, which decreased by 12% last year and increased by approximately 13% since 2014, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 69% of Scope 3 emissions.
Top Scope 3 Categories
Biogen's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Biogen has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Horizon Therapeutics Public Limited Company
Frequently Asked Questions
Common questions about Biogen's sustainability data and climate commitments